Skip to main content

Advertisement

SpringerLink
Log in

Beyond Serous: Treatment Options for Rare Endometrial Cancers

  • Gynecologic Cancers (JS Ferriss, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Rare endometrial cancers are high-grade, aggressive malignancies which are often diagnosed at an advanced stage, and account for disproportionately more deaths than their more common low-grade counterparts. Standard of care includes a combination of surgery, radiation, and chemotherapy. Surgery consists of complete hysterectomy, and more recent evidence supports replacing a full lymphadenectomy with sentinel node mapping. Paclitaxel and carboplatin remain the mainstays of chemotherapy, while current studies incorporating immunotherapy will inform future practice. Whether and how to incorporate radiation remains controversial, and certain histologic subtypes, such as carcinosarcomas, may benefit from radiation more than others. Owing to their relative rarity, it is difficult to conduct clinical trials in this patient population, which has hindered the development of effective therapies for rare malignancies. Molecular profiling has offered insight into the pathogenesis of rare endometrial cancers, providing actionable targets for personalized therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Matsuzaki S, Klar M, Matsuzaki S, Roman LD, Sood AK, Matsuo K. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. Gynecol Oncol. 2021;160(2):586–601.

    Article  PubMed  CAS  Google Scholar 

  2. Thomas M, Mariani A, Wright JD, Madarek EO, Powell MA, Mutch DG, et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. Gynecol Oncol. 2008;108(2):293–7.

    Article  PubMed  CAS  Google Scholar 

  3. Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.

    Article  Google Scholar 

  4. Cantrell LA, Blank SV, Duska LR. Uterine carcinosarcoma: a review of the literature. Gynecol Oncol. 2015;137(3):581–8.

    Article  PubMed  Google Scholar 

  5. Toboni MD, Crane EK, Brown J, Shushkevich A, Chiang S, Slomovitz BM, et al. Uterine carcinosarcomas: from pathology to practice. Gynecol Oncol. 2021;162(1):235–41.

    Article  PubMed  CAS  Google Scholar 

  6. Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, et al. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell. 2017;31(3):411–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Crane E, Naumann W, Tait D, Higgins R, Herzog T, Brown J. Molecular variations in uterine carcinosarcomas identify therapeutic opportunities. Int J Gynecol Cancer. 2020;30(4):480–4.

    Article  PubMed  Google Scholar 

  8. Fadare O, Liang SX, Ulukus EC, Chambers SK, Zheng W. Precursors of endometrial clear cell carcinoma. Am J Surg Pathol. 2006;30(12):1519–30.

    Article  PubMed  Google Scholar 

  9. Le Gallo M, Rudd ML, Urick ME, Hansen NF, Zhang S, Program NCS, et al. Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. Cancer. 2017;123(17):3261–8.

    Article  PubMed  Google Scholar 

  10. Urick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer. 2019;19(9):510–21.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. AlHilli M, Elson P, Rybicki L, Amarnath S, Yang B, Michener CM, et al. Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomes. Int J Gynecol Cancer. 2019;29(7):1126–33.

    Article  PubMed  Google Scholar 

  12. Tung HJ, Wu RC, Lin CY, Lai CH. Rare subtype of endometrial cancer: undifferentiated/dedifferentiated endometrial carcinoma, from genetic aspects to clinical practice. Int J Mol Sci. 2022;23(7).

  13. Kuhn E, Ayhan A, Bahadirli-Talbott A, Zhao C, Shih IM. Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma. Am J Surg Pathol. 2014;38(5):660–5.

    Article  PubMed  Google Scholar 

  14. Pors J, Segura S, Chiu DS, Almadani N, Ren H, Fix DJ, et al. Clinicopathologic characteristics of mesonephric adenocarcinomas and mesonephric-like adenocarcinomas in the gynecologic tract: a multi-institutional study. Am J Surg Pathol. 2021;45(4):498–506.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Santoro A, Angelico G, Travaglino A, Inzani F, Arciuolo D, Valente M, et al. New pathological and clinical insights in endometrial cancer in view of the updated ESGO/ESTRO/ESP guidelines. Cancers (Basel). 2021;13(11).

  16. Schlechtweg K, Chen L, St Clair CM, Tergas AI, Khoury-Collado F, Hou JY, et al. Neuroendocrine carcinoma of the endometrium: disease course, treatment, and outcomes. Gynecol Oncol. 2019;155(2):254–61.

    Article  PubMed  Google Scholar 

  17. Wang J, Wieslander C, Hansen G, Cass I, Vasilev S, Holschneider CH. Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecol Oncol. 2006;101(1):120–5.

    Article  PubMed  Google Scholar 

  18. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009;27(32):5331–6.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Fader AN, Seamon LG, Escobar PF, Frasure HE, Havrilesky LA, Zanotti KM, et al. Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers. Gynecol Oncol. 2012;126(2):180–5.

    Article  PubMed  Google Scholar 

  20. Perrone E, Capasso I, Pasciuto T, Gioe A, Gueli Alletti S, Restaino S, et al. Laparoscopic vs. robotic-assisted laparoscopy in endometrial cancer staging: large retrospective single-institution study. J Gynecol Oncol. 2021;32(3):e45.

  21. Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, et al. Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese gynecologic oncology group. Gynecol Oncol. 2016;141(3):447–53.

    Article  PubMed  Google Scholar 

  22. Havrilesky LJ, Cragun JM, Calingaert B, Synan I, Secord AA, Soper JT, et al. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol. 2005;99(3):689–95.

    Article  PubMed  Google Scholar 

  23. Huang AB, Wu J, Chen L, Albright BB, Previs RA, Moss HA, et al. Neoadjuvant chemotherapy for advanced stage endometrial cancer: a systematic review. Gynecol Oncol Rep. 2021;38:100887.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Khouri OR, Frey MK, Musa F, Muggia F, Lee J, Boyd L, et al. Neoadjuvant chemotherapy in patients with advanced endometrial cancer. Cancer Chemother Pharmacol. 2019;84(2):281–5.

    Article  PubMed  Google Scholar 

  25. Schlappe BA, Weaver AL, McGree ME, Ducie J, Zahl Eriksson AG, Dowdy SC, et al. Multicenter study comparing oncologic outcomes after lymph node assessment via a sentinel lymph node algorithm versus comprehensive pelvic and paraaortic lymphadenectomy in patients with serous and clear cell endometrial carcinoma. Gynecol Oncol. 2020;156(1):62–9.

    Article  PubMed  Google Scholar 

  26. Cusimano MC, Vicus D, Pulman K, Maganti M, Bernardini MQ, Bouchard-Fortier G, et al. Assessment of sentinel lymph node biopsy vs lymphadenectomy for intermediate- and high-grade endometrial cancer staging. JAMA Surg. 2021;156(2):157–64.

    Article  PubMed  Google Scholar 

  27. Marchocki Z, Cusimano MC, Clarfield L, Kim SR, Fazelzad R, Espin-Garcia O, et al. Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. Am J Obstet Gynecol. 2021;225(4):367 e1- e39.

  28. Cantrell LA, Havrilesky L, Moore DT, O'Malley D, Liotta M, Secord AA, et al. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol. 2012;127(1):22–6.

    Article  PubMed  Google Scholar 

  29. Wright JD, Seshan VE, Shah M, Schiff PB, Burke WM, Cohen CJ, et al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol. 2008;199(5):536 e1-8.

  30. Matsuo K, Omatsu K, Ross MS, Johnson MS, Yunokawa M, Klobocista MM, et al. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Gynecol Oncol. 2017;145(1):78–87.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Hamilton SN, Tinker AV, Kwon J, Lim P, Kong I, Sihra S, et al. Treatment and outcomes in undifferentiated and dedifferentiated endometrial carcinoma. J Gynecol Oncol. 2022;33(3):e25.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Vandenput I, Trovik J, Vergote I, Moerman P, Leunen K, Berteloot P, et al. The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study. Int J Gynecol Cancer. 2011;21(2):332–6.

    Article  PubMed  Google Scholar 

  33. Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, et al. Clear cell carcinoma of the endometrium. Gynecol Oncol. 2022;164(3):658–66.

    Article  PubMed  CAS  Google Scholar 

  34. Powell MA, Filiaci VL, Hensley ML, Huang HQ, Moore KN, Tewari KS, et al. Randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and ifosfamide in patients with carcinosarcoma of the uterus or ovary: an NRG Oncology Trial. J Clin Oncol. 2022;40(9):968–77.

    Article  PubMed  CAS  Google Scholar 

  35. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–9.

    Article  PubMed  CAS  Google Scholar 

  36. Einstein MH, Klobocista M, Hou JY, Lee S, Mutyala S, Mehta K, et al. Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. Gynecol Oncol. 2012;124(1):26–30.

    Article  PubMed  CAS  Google Scholar 

  37. Rubinstein MM, Dickinson S, Narayan P, Zhou Q, Iasonos A, Ma W, et al. Bevacizumab in advanced endometrial cancer. Gynecol Oncol. 2021;161(3):720–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res. 2020;26(15):3928–35.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Menderes G, Bonazzoli E, Bellone S, Black J, Predolini F, Pettinella F, et al. SYD985, a Novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/Neu expression. Clin Cancer Res. 2017;23(19):5836–45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10.

    Article  PubMed  CAS  Google Scholar 

  41. Bhangoo MS, Boasberg P, Mehta P, Elvin JA, Ali SM, Wu W, et al. Tumor mutational burden guides therapy in a treatment refractory POLE-mutant uterine carcinosarcoma. Oncologist. 2018;23(5):518–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 2020;38(26):2981–92.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Rubinstein MM, Hyman DM, Caird I, Won H, Soldan K, Seier K, et al. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer. 2020;126(6):1274–82.

    Article  PubMed  CAS  Google Scholar 

  44. Banerjee S, Stewart J, Porta N, Toms C, Leary A, Lheureux S, et al. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). Int J Gynecol Cancer. 2021;31(11):1471–5.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Dwivedi SKD, Rao G, Dey A, Buechel M, Zhang Y, Zhang M, et al. Targeting the TGFbeta pathway in uterine carcinosarcoma. Cell Stress. 2020;4(11):252–60.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, et al. Clinical utility of prospective molecular characterization in advanced endometrial cancer. Clin Cancer Res. 2018;24(23):5939–47.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Levine Cancer Institute, Atrium Health System, 1021 Morehead Medical Drive, Suite 2100, Charlotte, NC, 28204, USA

    Erin Crane MD, MPH

Authors
  1. Erin Crane MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erin Crane MD, MPH.

Ethics declarations

Conflict of Interest

Erin Crane declares no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Gynecologic Cancers

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crane, E. Beyond Serous: Treatment Options for Rare Endometrial Cancers. Curr. Treat. Options in Oncol. 23, 1590–1600 (2022). https://doi.org/10.1007/s11864-022-01014-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-022-01014-7

Keywords

Search

Navigation